venetoclax Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5133 1257044-40-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • venclyxto
  • venetoclax
  • ABT-199
  • venclexta
  • GDC-0199
Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.
  • Molecular weight: 868.45
  • Formula: C45H50ClN7O7S
  • CLOGP: 10.31
  • LIPINSKI: 3
  • HAC: 14
  • HDO: 3
  • TPSA: 172.03
  • ALOGS: -5.97
  • ROTB: 12

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 20, 2019 PMDA AbbVie GK
Dec. 5, 2016 EMA AbbVie Ltd
April 11, 2016 FDA ABBVIE INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 950.83 23.88 671 8821 334877 46341693
Off label use 522.71 23.88 501 8991 379340 46297230
Chronic lymphocytic leukaemia 419.61 23.88 101 9391 2799 46673771
Acute myeloid leukaemia 404.25 23.88 143 9349 15635 46660935
Intentional product use issue 400.62 23.88 201 9291 52579 46623991
Febrile neutropenia 392.62 23.88 242 9250 94385 46582185
Neutropenia 308.44 23.88 245 9247 142959 46533611
Tumour lysis syndrome 302.88 23.88 95 9397 7141 46669429
Hospice care 202.83 23.88 65 9427 5230 46671340
Sepsis 128.69 23.88 148 9344 135866 46540704
Pancytopenia 103.90 23.88 106 9386 84952 46591618
Thrombocytopenia 102.01 23.88 127 9365 126454 46550116
Pneumonia 91.05 23.88 221 9271 376099 46300471
Cytopenia 90.93 23.88 40 9452 7728 46668842
Disease progression 83.95 23.88 98 9394 91202 46585368
Neutrophil count decreased 79.83 23.88 68 9424 43358 46633212
Acute myeloid leukaemia recurrent 74.02 23.88 22 9470 1374 46675196
Platelet count decreased 68.99 23.88 93 9399 99931 46576639
Infection 68.58 23.88 108 9384 133484 46543086
Lymphadenopathy 64.75 23.88 54 9438 33434 46643136
Mantle cell lymphoma 57.54 23.88 15 9477 576 46675994
Bone marrow transplant 55.67 23.88 15 9477 655 46675915
White blood cell count decreased 55.19 23.88 89 9403 112142 46564428
Pyrexia 51.85 23.88 172 9320 348630 46327940
Rhinovirus infection 50.04 23.88 21 9471 3615 46672955
Pneumonia fungal 47.32 23.88 21 9471 4139 46672431
Non-small cell lung cancer 46.10 23.88 19 9473 3125 46673445
Blood lactate dehydrogenase increased 45.84 23.88 36 9456 20464 46656106
Hyperuricaemia 44.79 23.88 21 9471 4696 46671874
COVID-19 42.36 23.88 33 9459 18542 46658028
T-cell prolymphocytic leukaemia 39.13 23.88 6 9486 10 46676560
Chronic lymphocytic leukaemia refractory 38.35 23.88 7 9485 46 46676524
Myelodysplastic syndrome 38.20 23.88 29 9463 15682 46660888
Terminal ileitis 36.75 23.88 8 9484 139 46676431
Hospitalisation 36.35 23.88 54 9438 63331 46613239
Drug ineffective 35.53 23.88 52 9440 677786 45998784
Bone marrow failure 34.39 23.88 36 9456 29633 46646937
Pain 33.21 23.88 29 9463 476919 46199651
Diffuse large B-cell lymphoma 31.86 23.88 18 9474 5920 46670650
Blood phosphorus increased 31.32 23.88 14 9478 2805 46673765
Acute myeloid leukaemia refractory 30.58 23.88 5 9487 15 46676555
Nonspecific reaction 29.94 23.88 12 9480 1838 46674732
Febrile bone marrow aplasia 29.44 23.88 18 9474 6844 46669726
Pleural effusion 28.15 23.88 56 9436 82896 46593674
Allogenic stem cell transplantation 27.77 23.88 4 9488 3 46676567
Transformation to acute myeloid leukaemia 26.53 23.88 6 9486 125 46676445
Arthralgia 25.55 23.88 22 9470 364581 46311989
Headache 24.69 23.88 37 9455 478315 46198255
Aspergillus infection 24.38 23.88 16 9476 6874 46669696
Campylobacter gastroenteritis 24.31 23.88 7 9485 391 46676179
Fungal sepsis 24.12 23.88 9 9483 1138 46675432

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1068.07 20.17 1149 15952 356134 29579243
Off label use 826.33 20.17 850 16251 248440 29686937
Tumour lysis syndrome 570.59 20.17 230 16871 12655 29922722
Chronic lymphocytic leukaemia 566.52 20.17 176 16925 4452 29930925
Intentional product use issue 539.85 20.17 306 16795 36134 29899243
Acute myeloid leukaemia 531.10 20.17 241 16860 17765 29917612
Febrile neutropenia 442.05 20.17 413 16688 106280 29829097
Neutropenia 344.58 20.17 394 16707 128146 29807231
Hospice care 299.79 20.17 108 16993 4344 29931033
Pneumonia 144.89 20.17 468 16633 333838 29601539
Lymphadenopathy 137.86 20.17 113 16988 24263 29911114
Cytopenia 134.62 20.17 74 17027 8182 29927195
Disease progression 131.69 20.17 193 16908 79681 29855696
Sepsis 117.28 20.17 258 16843 146137 29789240
COVID-19 105.53 20.17 85 17016 17793 29917584
Mantle cell lymphoma 102.26 20.17 37 17064 1504 29933873
Thrombocytopenia 92.61 20.17 226 16875 136818 29798559
Infection 90.73 20.17 161 16940 77913 29857464
Pancytopenia 87.01 20.17 166 16935 84886 29850491
Chronic lymphocytic leukaemia recurrent 85.80 20.17 24 17077 414 29934963
Lymphocyte count increased 68.46 20.17 32 17069 2510 29932867
Hyperphosphataemia 65.72 20.17 30 17071 2229 29933148
Autoimmune haemolytic anaemia 65.10 20.17 36 17065 4023 29931354
Platelet count decreased 63.23 20.17 167 16934 105962 29829415
Acute myeloid leukaemia recurrent 56.08 20.17 24 17077 1528 29933849
Splenomegaly 55.10 20.17 52 17049 13428 29921949
Neutrophil count decreased 55.09 20.17 92 17009 42362 29893015
Transplant 48.34 20.17 17 17084 635 29934742
Hospitalisation 47.10 20.17 88 17013 44231 29891146
Blood phosphorus increased 47.00 20.17 25 17076 2586 29932791
Pyrexia 45.94 20.17 306 16795 294183 29641194
Toxicity to various agents 45.78 20.17 22 17079 177161 29758216
Pneumonia fungal 45.28 20.17 32 17069 5501 29929876
Completed suicide 45.07 20.17 3 17098 99489 29835888
Acute myeloid leukaemia refractory 42.97 20.17 8 17093 16 29935361
COVID-19 pneumonia 41.24 20.17 28 17073 4512 29930865
Mantle cell lymphoma refractory 41.23 20.17 10 17091 95 29935282
White blood cell count decreased 40.08 20.17 122 16979 83825 29851552
Influenza 35.17 20.17 77 17024 43321 29892056
Hyperuricaemia 35.05 20.17 31 17070 7363 29928014
Chronic lymphocytic leukaemia transformation 34.50 20.17 10 17091 197 29935180
Blood count abnormal 33.17 20.17 37 17064 11615 29923762
Bone marrow transplant 31.81 20.17 14 17087 954 29934423
Stem cell transplant 31.72 20.17 18 17083 2113 29933264
Leukaemia 31.55 20.17 21 17080 3276 29932101
Neutropenic sepsis 30.39 20.17 35 17066 11374 29924003
Myelodysplastic syndrome 30.31 20.17 45 17056 18733 29916644
Blood pressure increased 30.26 20.17 3 17098 71925 29863452
Drug interaction 30.18 20.17 42 17059 199526 29735851
Headache 30.00 20.17 36 17065 182270 29753107
Skin infection 29.60 20.17 26 17075 6118 29929259
Product dose omission issue 29.35 20.17 8 17093 91623 29843754
Hypogammaglobulinaemia 28.93 20.17 24 17077 5228 29930149
Depression 28.77 20.17 8 17093 90429 29844948
Somnolence 28.21 20.17 10 17091 96753 29838624
Overdose 27.70 20.17 7 17094 84330 29851047
Blood uric acid abnormal 27.69 20.17 7 17094 80 29935297
Lymphocytosis 27.61 20.17 16 17085 1954 29933423
Bacteraemia 27.60 20.17 39 17062 15521 29919856
Blood uric acid increased 26.08 20.17 24 17077 5999 29929378
Chronic lymphocytic leukaemia refractory 26.06 20.17 7 17094 103 29935274
Diffuse large B-cell lymphoma 26.01 20.17 27 17074 7814 29927563
Blast cell count decreased 25.88 20.17 4 17097 0 29935377
Pruritus 25.77 20.17 18 17083 118186 29817191
Blood lactate dehydrogenase increased 24.53 20.17 43 17058 20558 29914819
Escherichia bacteraemia 24.25 20.17 17 17084 2885 29932492
Septic shock 22.82 20.17 84 17017 63523 29871854
Soft tissue infection 22.40 20.17 13 17088 1592 29933785
Blastic plasmacytoid dendritic cell neoplasia 22.29 20.17 6 17095 89 29935288
Ureteric compression 22.22 20.17 5 17096 33 29935344
Anxiety 21.92 20.17 12 17089 89859 29845518
Condition aggravated 21.85 20.17 28 17073 137838 29797539
Chemotherapy 21.68 20.17 9 17092 531 29934846
Coronavirus infection 21.41 20.17 17 17084 3481 29931896
Haemoglobin abnormal 20.87 20.17 16 17085 3113 29932264
Respiratory tract infection 20.62 20.17 34 17067 15472 29919905
T-cell prolymphocytic leukaemia 20.57 20.17 5 17096 48 29935329
Lymphocyte count decreased 20.43 20.17 38 17063 19017 29916360
Mantle cell lymphoma recurrent 20.25 20.17 8 17093 415 29934962
Aspergillus infection 20.22 20.17 27 17074 10187 29925190

Pharmacologic Action:

SourceCodeDescription
ATC L01XX52 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
FDA PE N0000009176 Increased Cellular Death
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA EPC N0000192515 BCL-2 Inhibitor
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:68495 type i programmed cell-death inducer
CHEBI has role CHEBI:133022 bcl-2 inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic lymphoid leukemia, disease indication 92814006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.0 acidic
pKa2 13.01 acidic
pKa3 7.73 Basic
pKa4 4.24 Basic
pKa5 3.47 Basic
pKa6 0.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2021 NEW CHEMICAL ENTITY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2021 NEW CHEMICAL ENTITY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2021 NEW CHEMICAL ENTITY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2021 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2021 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2021 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2022 VENETOCLAX IN COMBINULLTION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2022 VENETOCLAX IN COMBINULLTION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2022 VENETOCLAX IN COMBINULLTION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2023 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2023 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2023 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Oct. 16, 2023 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Oct. 16, 2023 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Oct. 16, 2023 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2025 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2025 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2025 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2025 INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2025 INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2025 INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2026 TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2026 TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2026 TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Apoptosis regulator Bcl-2 Cytosolic other INHIBITOR Ki 11 SCIENTIFIC LITERATURE DRUG LABEL
Bcl-2-like protein 1 Cytosolic other INHIBITOR Ki 7.32 SCIENTIFIC LITERATURE
Apoptosis regulator Bcl-W Cytosolic other INHIBITOR Ki 6.61 SCIENTIFIC LITERATURE

External reference:

IDSource
D10679 KEGG_DRUG
4035629 VANDF
C3641087 UMLSCUI
CHEBI:133021 CHEBI
LBM PDB_CHEM_ID
CHEMBL3137309 ChEMBL_ID
49846579 PUBCHEM_CID
C579720 MESH_SUPPLEMENTAL_RECORD_UI
9925 INN_ID
DB11581 DRUGBANK_ID
N54AIC43PW UNII
8318 IUPHAR_LIGAND_ID
1747556 RXNORM
240227 MMSL
31601 MMSL
d08429 MMSL
016803 NDDF
720491001 SNOMEDCT_US
763511000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Venclexta HUMAN PRESCRIPTION DRUG LABEL 1 0074-0561 TABLET, FILM COATED 10 mg ORAL NDA 28 sections
Venclexta HUMAN PRESCRIPTION DRUG LABEL 1 0074-0566 TABLET, FILM COATED 50 mg ORAL NDA 28 sections
Venclexta HUMAN PRESCRIPTION DRUG LABEL 1 0074-0576 TABLET, FILM COATED 100 mg ORAL NDA 28 sections